Ventas price target raised to $93 from $85 at Jefferies

Jefferies raised the firm’s price target on Ventas (VTR) to $93 from $85 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for Healthcare REITs. The firm expects another challenging year for lab landlords as elevated market vacancy and a 9.6% decline in trailing-12-month biotech funding will drive below-average retention in 2026, the analyst tells investors in a research note. For Ventas, Jefferies notes that Senior Housing net operating income growth should be among the strongest across the REIT sector, as COVID-19 and an elevated cost of capital have slowed new construction, while demographic tailwinds continue to strengthen as the Baby Boomers age into the 80+ demographic.